69 related articles for article (PubMed ID: 34284273)
1. The spectrum of GATA2 deficiency syndrome.
Calvo KR; Hickstein DD
Blood; 2023 Mar; 141(13):1524-1532. PubMed ID: 36455197
[TBL] [Abstract][Full Text] [Related]
2. Generation of heterozygous (MCRIi030-A-1) and homozygous (MCRIi030-A-2) NR2F2/COUP-TFII knockout human iPSC lines.
Ferreira LGA; Cabral-da-Silva MC; Pachernegg S; van den Bergen JA; Robevska G; Vlahos K; Howden SE; Ng ES; Dias-da-Silva MR; Sinclair AH; Ayers KL
Stem Cell Res; 2024 Apr; 76():103374. PubMed ID: 38458031
[TBL] [Abstract][Full Text] [Related]
3. Generation of CRISPR/Cas9 edited human induced pluripotent stem cell line carrying the heterozygous p.H695VfsX5 frameshift mutation in the exon 10 of the PKP2 gene.
Pierre B; Laëtitia DB; Camille B; Claire P; Elise B; Estelle G; Vincent F; Eric V
Stem Cell Res; 2024 Apr; 76():103341. PubMed ID: 38382214
[TBL] [Abstract][Full Text] [Related]
4. Perturbed collagen metabolism underlies lymphatic recanalization failure in Gata2 heterozygous deficient mice.
Watanabe-Asaka T; Hayashi M; Harada T; Uemura S; Takai J; Nakamura Y; Moriguchi T; Kawai Y
J Biochem; 2024 Apr; 175(5):551-560. PubMed ID: 38168819
[TBL] [Abstract][Full Text] [Related]
5. Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.
Darle A; Mahiet T; Aubin D; Doyen M; El Kassar L; Parfait B; Lemaitre G; Baldeschi C; Allouche J; Holic N
Front Cell Dev Biol; 2024; 12():1359561. PubMed ID: 38481529
[TBL] [Abstract][Full Text] [Related]
6. Modeling rare diseases with induced pluripotent stem cell technology.
Anderson RH; Francis KR
Mol Cell Probes; 2018 Aug; 40():52-59. PubMed ID: 29307697
[TBL] [Abstract][Full Text] [Related]
7. A Nationwide Study of GATA2 Deficiency in Italy Reveals Novel Symptoms and Genotype-phenotype Association.
Roncareggi S; Girardi K; Fioredda F; Pedace L; Arcuri L; Badolato R; Bonanomi S; Borlenghi E; Cirillo E; Coliva T; Consonni F; Conti F; Farruggia P; Gambineri E; Guerra F; Locatelli F; Mancuso G; Marzollo A; Masetti R; Micalizzi C; Onofrillo D; Piccini M; Pignata C; Raddi MG; Santini V; Vendemini F; Biondi A; Saettini F
J Clin Immunol; 2023 Nov; 43(8):2192-2207. PubMed ID: 37837580
[TBL] [Abstract][Full Text] [Related]
8. Introduction to a review series on germ line predisposition to hematologic malignancies: time to consider germ line testing.
Cazzola M
Blood; 2023 Mar; 141(13):1509-1512. PubMed ID: 36787501
[No Abstract] [Full Text] [Related]
9. Many signs, one mutation: Early onset of de novo GATA2 deficiency syndrome. A case report.
Blanco ML; Torrent M; Bussaglia E; Badell I; Nomdedéu JF
Clin Case Rep; 2020 Dec; 8(12):3193-3197. PubMed ID: 33363905
[TBL] [Abstract][Full Text] [Related]
10. GATA2: sense and (anti)sensibility.
Gibbons MD; Bungert J
Blood; 2024 May; 143(22):2224-2225. PubMed ID: 38814656
[No Abstract] [Full Text] [Related]
11. GATA2 deficiency syndrome: A decade of discovery.
Homan CC; Venugopal P; Arts P; Shahrin NH; Feurstein S; Rawlings L; Lawrence DM; Andrews J; King-Smith SL; Harvey NL; Brown AL; Scott HS; Hahn CN
Hum Mutat; 2021 Nov; 42(11):1399-1421. PubMed ID: 34387894
[TBL] [Abstract][Full Text] [Related]
12. GATA2 rs2335052 and GATA2 rs78245253 single-nucleotide polymorphisms in Chinese patients with acute myelocytic leukemia.
Fang F; Xu J; Kang Y; Ren H; Muyey DM; Chen X; Tan Y; Xu Z; Wang H
Int J Lab Hematol; 2021 Dec; 43(6):1491-1500. PubMed ID: 34374210
[TBL] [Abstract][Full Text] [Related]
13. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency.
Marin-Bejar O; Romero-Moya D; Rodriguez-Ubreva J; Distefano M; Lessi F; Aretini P; Liquori A; Castaño J; Kozyra E; Kotmayer L; Bueno C; Cervera J; Rodriguez-Gallego JC; Nomdedeu JF; Murillo-Sanjuán L; De Heredia CD; Pérez-Martinez A; López-Cadenas F; Martínez-Laperche C; Dorado-Herrero N; Marco FM; Prósper F; Menendez P; Valcárcel D; Ballestar E; Bödör C; Bigas A; Catalá A; Wlodarski MW; Giorgetti A
Haematologica; 2023 Sep; 108(9):2551-2557. PubMed ID: 36815365
[No Abstract] [Full Text] [Related]
14. Gata2 haploinsufficiency promotes proliferation and functional decline of hematopoietic stem cells with myeloid bias during aging.
Abdelfattah A; Hughes-Davies A; Clayfield L; Menendez-Gonzalez JB; Almotiri A; Alotaibi B; Tonks A; Rodrigues NP
Blood Adv; 2021 Oct; 5(20):4285-4290. PubMed ID: 34496012
[TBL] [Abstract][Full Text] [Related]
15. Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development.
Bigas A; Galán Palma L; Kartha GM; Giorgetti A
Stem Cells Transl Med; 2022 Nov; 11(11):1123-1134. PubMed ID: 36398586
[TBL] [Abstract][Full Text] [Related]
16. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
Kotmayer L; Romero-Moya D; Marin-Bejar O; Kozyra E; Català A; Bigas A; Wlodarski MW; Bödör C; Giorgetti A
Br J Haematol; 2022 Nov; 199(4):482-495. PubMed ID: 35753998
[TBL] [Abstract][Full Text] [Related]
17. Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency.
Castaño J; Romero-Moya D; Richaud-Patin Y; Giorgetti A
Stem Cell Res; 2021 Aug; 55():102445. PubMed ID: 34284273
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
